The DOI matches its Crossref record; 32 of the 44 references it cites were found in a registry or an index, and 12 are not checked yet; none of the 37 sources its claims cite is checked for support yet.
p53 Deficiency Rescues the Adverse Effects of Telomere Loss and Cooperates with Telomere Dysfunction to Accelerate Carcinogenesis
Open accessAbstract
Maintenance of telomere length and function is critical for the efficient proliferation of eukaryotic cells. Here, we examine the interactions between telomere dysfunction and p53 in cells and organs of telomerase-deficient mice. Coincident with severe telomere shortening and associated genomic instability, p53 is activated, leading to growth arrest and/or apoptosis. Deletion of p53 significantly attenuated the adverse cellular and organismal effects of telomere dysfunction, but only during the earliest stages of genetic crisis. Correspondingly, the loss of telomere function and p53 deficiency cooperated to initiate the transformation process. Together, these studies establish a key role for p53 in the cellular response to telomere dysfunction in both normal and neoplastic cells, question the significance of crisis as a tumor suppressor mechanism, and identify a biologically relevant stage of advanced crisis, termed genetic catastrophe.
Checked 2026-10-06 · 12 references not checked yet
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In telomerase-deficient (mTR−/−) mice, critically short telomeres activate p53, and deleting p53 rescues the resulting apoptosis and cell-cycle arrest — but only during early "crisis." Loss of telomere function and p53 deficiency cooperate to initiate transformation, while telomerase reconstitution mainly benefits later stages of tumorigenesis.
Key findings
- Critical telomere shortening activates p53: p53 protein was detectable in G6 mTR−/− testis but not in mTR+/+ or G6 mTR−/− p53−/− littermates; >80% of G4 and G6 MEFs stained positive for p53 at passage 6 versus 21% of mTR+/+ MEFs. p21CIP1/WAF1 rose 3- to 4-fold in G6 versus G2 mTR−/− p53+/+ MEFs, and p53-dependent CAT reporter activity increased ~2-fold.
- p53 loss rescued telomere-dysfunction phenotypes early but not late: 15% of G4–G6 mTR−/− mice (86/565) were p53−/− versus 26% of G7–G8 mice (24/91) (p = 0.015); all G5 mTR−/− p53−/− testes had normal histology, but 3 of 7 G6 and all five G7–G8 samples showed germ cell depletion. G6 mTR−/− p53−/− MEFs showed a 3-fold increase in chromosome fusions (1.65, SD 2.59 vs 0.42, SD 0.71 per metaphase; p = 0.012), with no change in telomere length (75% reduction regardless of p53 status).
- Telomere dysfunction cooperated with p53 deficiency to initiate transformation: adding mTR suppressed Myc/RAS focus formation in G6 mTR−/− p53−/− MEFs, but mTR-transfected foci had higher subcloning efficiency (23/26, 89%) than vector foci (19/32, 59%; p = 0.018). Tumor formation in SCID mice was similar between groups.
- The authors propose dividing crisis into p53-dependent "early crisis" and p53-independent "genetic catastrophe," questioning crisis as a tumor suppressor mechanism.
Methods
- Mouse genetics: mTR+/− mice crossed with p53+/− mice to generate successive generations (G1–G8) of mTR−/− animals with p53+/+, +/−, and −/− genotypes in a mixed WW6/C57BL/6 background; p53 status maintained heterozygous during matings.
- Cellular/organ assays: immunoblotting and immunohistochemistry for p53 and p21, pG13CAT reporter assays, testis histology with TUNEL, BrdU/propidium iodide FACS cell-cycle profiles, flow FISH telomere length, and metaphase spreads for chromosome fusions.
- Transformation assays: Myc/RAS cotransfection of early-passage MEFs with empty vector or an mTR genomic fragment, scoring focus formation, subcloning efficiency, and tumor formation after subcutaneous injection into SCID mice.
Limitations
- Stated: the mechanisms by which tumorigenic potential is maintained in late stages of tumorigenesis despite telomere dysfunction "remain to be determined"; whether loss of TRF2 binding, short telomeres, or fusion-bridge-breakage cycles mediate the p53 induction described also remains undetermined.
- Evident from the text: the G7–G8 genotype comparison rests on small numbers (24 of 91 mice), and all mice are in a mixed genetic background, which the authors note required cousin mating to avoid substrains.
- Evident from the text: the transformation data are from cultured MEFs and SCID xenografts, and tumor weights/efficiency between mTR and vector lines were not significantly different, so the in vivo relevance of the initiation advantage is inferred rather than directly demonstrated.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
40 Own interpretation · 39 Own result · 21 Not checked yet · 6 Own method · 4 No basis given · 1 Check pending
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Correspondingly, the loss of telomere function and p53 deficiency cooperated to initiate the transformation process.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Coincident with severe telomere shortening and associated genomic instability, p53 is activated, leading to growth arrest and/or apoptosis.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This activity was strictly dependent upon p53, since p53−/− and G6 mTR−/− p53−/− MEF cultures showed only background levels of CAT activity.”
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We found that p53 mediates the adverse effects of critically shortened telomeres.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As shown in Figure 3A, DNA content analyses of G6 mTR−/− p53+/+ MEFs revealed a profile consistent with a biphasic block as evidenced by marked accumulation of cells in G1 and G2/M phases.”
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A check of a cited source is scheduled, or we don’t hold its full text yet; the claim is checked once it runs.
In the paper
“Indeed, analysis of metaphase spreads derived from G6 mTR−/− p53+/+ MEFs showed a rate of 0.42 (SD 0.71) chromosomal fusions per metaphase, a rate consistent with previous studies (Figure 3D) (Blasco et al. 1997; Greenberg et al. 1999; Rudolph et al. 1999”
What the sources say
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, p53-independent cell death becomes a more consistent feature in G7 and G8, since all of the five G7–G8 mTR−/− p53−/− testis samples showed significant germ cell depletion microscopically (Figure 2D).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, a relative increase in p53−/− mice was evident in G7 and G8 mTR−/− background (24% and 38%, respectively).”
plaincorrelationaln = 91 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Gross testis size was consistently rescued to near normal in G6 mTR−/− p53−/− mice compared to G6 mTR−/− p53+/+ littermates (see Figure 2A for representative comparison).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, loss of telomere function and p53 deficiency can cooperate to enhance transformation.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 36
- The quote only partly states this claim. 1
- Probably not a substantial claim. 16
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Deletion of p53 significantly attenuated the adverse cellular and organismal effects of telomere dysfunction, but only during the earliest stages of genetic crisis.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In contrast, mTR+/+ p53+/+ MEF cultures demonstrated 35% of cells in S phase and only 13% in G2/M.”
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In mTR+/+ testis, p53 status did not affect testicular volume or significantly alter the cytoarchitecture of seminiferous tubules (Figure 2A and Figure 2B).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Whereas only 21% of the mTR+/+ MEFs at passage 6 stained positive for p53, more than 80% of MEFs derived from G4 and G6 exhibited strong immunoreactivity to p53 (Figure 1B, compare [a] with [b] and [c]).”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“In male germ cells and lymphocytes, telomere loss elicits a strong apoptotic response, whereas MEFs experience a potent biphasic cell cycle block.”
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The mTR−/− mouse is a valid model for studying the consequences of telomere loss in vivo.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Whereas all G5 mTR−/− p53−/− testes exhibited normal histology, 3 of 7 G6 mTR−/− p53−/− samples still showed varying degrees of pathology (Table 1).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Accordingly, BrdU incorporation assay showed that 36% of the G6 mTR−/− p53+/+ cells were in G1 phase, 3% were in S phase, and 40% were in G2/M (Figure 3A, top panel).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Immunoprecipitation and Western blot analysis readily detected p53 in lysates from G6 mTR−/− testis, but not in lysates derived from age-matched mTR+/+ testis or from G6 mTR−/− p53−/− littermate controls (Figure 1A).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“This induction of p53 coincides with the dramatic increase in apoptosis (as assessed by TUNEL) and decreased cellularity in the G6 mTR−/− testis (Lee et al. 1998”
What the sources say
- Not checked yetcites Lee et al. 1998 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Significantly, loss of p53 rescues the cell cycle arrest in MEFs and the apoptotic elimination of male germ cells.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The mTR−/− mouse is a valid model for studying the consequences of telomere loss in vivo.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“loss of p53 abrogated this block.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Significantly, 15% of the G4–G6 mTR−/− mice (86 out of 565 mice) were p53−/− compared to 26% of the G7–G8 mTR−/− mice (24 of 91 mice) (p = 0.015 by Fisher’s two-sided t test) (Figure 1E).”
plaincorrelationaln = 565 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“By comparison, G6 mTR−/− p53−/− MEFs exhibited 1.65 (SD 2.59) fusions per metaphase, a 3-fold increase (p = 0.012).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the case of MEFs, this arrest occurs in concert with the stabilization and activation of the p53 protein, evident in p53-dependent reporter assays and activation of p21CIP1/WAF1.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The mTR−/− mouse is a valid model for studying the consequences of telomere loss in vivo.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Similar differences were observed in low-density seeding experiments (data not shown).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“In human cells, a critical telomere length is eventually reached that induces cellular senescence, thus limiting the replicative capacity of cultured cells at the Hayflick limit (Hayflick and Moorhead 1961”
What the sources say
- Not checked yetcites Hayflick and Moorhead 1961 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
In the paper
“In primary cells deficient for Rb and p53, continued cellular growth beyond the Hayflick limit results in severe telomere shortening, marked genetic instability, and massive cell death—a period referred to as crisis (Counter et al. 1992”
What the sources say
- Not checked yetcites Counter et al. 1992 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Ectopically expressed hTERT maintains telomere length and allows unlimited growth (Bodnar et al. 1998; Counter et al. 1998; Vaziri and Benchimol 1998”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The notion that telomere function may indeed be required for immortalization is supported by the frequent activation of telomerase or ALT in human cancers (Kim et al. 1994; Bryan et al. 1995”
What the sources say
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The telomere signal that activates this senescent program operates through the RB and p53 pathways, since cell division beyond the Hayflick limit can occur after antisense neutralization (Hara et al. 1991”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“Telomerase is comprised of essential catalytic (telomerase reverse transcriptase [TERT]) and RNA components (telomerase RNA [TR]) (reviewed in Greider 1998”
What the sources say
- Not checked yetcites Greider 1998 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Strikingly, as mTR−/− mice advance with age and generation, an increase in cancer incidence is observed presumably due to increased genetic instability caused by telomere shortening, repeated chromosomal fusion-bridge-breakage cycles, and chromosomal loss (Rudolph et al. 1999”
What the sources say
- Not checked yetcites Rudolph et al. 1999 source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Due to the very long telomeres of Mus musculus, critical reduction in telomere length and chromosomal instability is only seen following extensive passage of mTR−/− cells (Niida et al. 1998”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The RNA subunit provides the template for telomere repeat synthesis (Greider and Blackburn 1989; Yu et al. 1990”
What the sources say
- Not checked yetcites Greider and Blackburn 1989
- Not checked yetcites Yu et al. 1990
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“although immortalization of some epithelial cells requires not only TERT expression but also compromise of the RB pathway (Kiyono et al. 1998”
What the sources say
- Not checked yetcites Kiyono et al. 1998 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although loss of telomere and p53 function facilitates initiation of transformation, the reconstitution of telomerase activity greatly improved the capacity of transformed foci to yield immortal cultures.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Because G2 mTR−/− and G6 mTR−/− MEFs both lack telomerase activity, we conclude that telomere shortening or associated chromosome fusions and breakage rather than telomerase deficiency per se signals to p53 and accounts for p21CIP1/WAF1 induction.”
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, the rampant genetic instability of the G7 and G8 mTR−/− p53−/− cells is associated with loss of cell viability despite p53 deficiency, implying that advanced genomic catastrophe gives way to a p53-independent process.”
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The mTR−/− mouse is a valid model for studying the consequences of telomere loss in vivo.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These results indicate that telomere dyfunction acts synergistically with p53 deficiency to initiate malignant transformation, presumably by enhancing genetic instability.”
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Continued proliferation in the absence of the p53 checkpoint may lead to an increased loss of telomere sequences and therefore account for the increased frequency of chromosome fusions.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“For these matings, the p53 status was maintained in the heterozygous state to avoid potential broad genomic effects arising from p53 deficiency.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The ability of exogenous telomerase to reduce focus formation in p53 null cells with short dysfunctional telomeres suggests that genetic instability associated with telomere loss can serve as an engine driving initiation of transformation, but only in the absence of functional p53 (Figure 5).”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Focus formation reflects the earliest stages of oncogenic transformation.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Early crisis accounts for efficient germ cell depletion in G6 mTR−/− p53+/+, whereas the altered histology of G7 and G8 mTR−/− p53−/− testis provides experimental support for late crisis.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The mTR−/− mouse is a valid model for studying the consequences of telomere loss in vivo.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Together, these data indicate that p53 deficiency restores neither telomere length nor function in the telomerase-deficient mouse.”
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“This mating scheme also produced p53+/+ and p53−/− littermate controls for each mTR−/− generation.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
None of the sources cited for this claim have been checked yet.
In the paper
“Telomere shortening in mTR−/− mice results in loss of telomere function and chromosome end-to-end fusion (Blasco et al. 1997; Rudolph et al. 1999”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The observation that mTR expression facilitates subcloning efficiency of Myc/RAS-transformed late-generation mTR−/− cells supports the importance of telomere maintenance mechanisms during later stages of carcinogenesis.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Induction of double strand breaks in DNA by ionizing radiation or genotoxic chemotherapy leads to the rapid stabilization of p53 through phosphorylation of its N terminus (Shieh et al. 1997; Siliciano et al. 1997”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Together with previous work, our data indicated that, first, during the early stages of tumorigenesis, cells suffer telomere shortening, and second, that telomerase activation is advantageous primarily in later stages of tumorigenesis.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Many human tumors that are telomerase positive still have short telomeres.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cells with short telomeres and intact p53-mediated DNA damage responses may be more efficiently “culled” from the population (via apoptosis or arrest); therefore, p53 null cells may accumulate more end-to-end fusions than their p53+/+ counterparts.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Once both telomere function and p53 have been impaired, the fate of the cell is unpredictable and depends on other stochastic genetic changes.”
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“This stabilization results in either cell cycle arrest via transcriptional induction of the p21CIP1/WAF1 CDK inhibitor or apoptosis (reviewed in Levine 1997”
What the sources say
- Not checked yetcites Levine 1997 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Loss of p53 can circumvent this checkpoint, leading eventually to p53-independent apoptosis, perhaps as a consequence of uncontrolled chromosome fusion-bridge-breakage cycles and progressive genomic instability.”
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, both the apoptotic response and cell cycle arrest induced by telomere dysfunction are mediated by p53.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“For telomere length determination of MEFs, littermate MEF cultures were assayed simultaneously to reduce experimental variability.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“At least two independent determinations of the same cultures were performed.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Day to day variations in the linearity of the flow cytometer were controlled by the use of FITC-labeled fluorescence beads (Flow Cytometry Standards Corporation).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Three independent age-matched sets of animals were used.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In mTR−/− INK4a−/− mice, it is likely that telomere dysfunction activates p53 via a DNA damage signaling pathway and results in growth arrest or apoptosis, limiting the efficiency of carcinogenesis”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper relies on this without support.
The signals and pathways mediating the cellular responses associated with telomere dysfunction have yet to be defined in mammalian cells.
“The signals and pathways mediating these cellular responses associated with telomere dysfunction have yet to be defined in mammalian cells.”
The paper relies on this without support.
The RAD9 and MEC1 DNA damage response pathways in yeast are similar to the p53 checkpoint in mammalian cells.
“The RAD9 and MEC1 DNA damage response pathways in yeast are thought to be similar to the p53 checkpoint in mammalian cells.”
The paper relies on this without support.
The mTR−/− mouse is a valid model for studying the consequences of telomere loss in vivo.
“The mTR−/− mouse serves as a model to study the consequences of telomere loss in vivo.”
The paper relies on this without support.
Focus formation reflects the earliest stages of oncogenic transformation.
“Focus formation is thought to reflect the earliest stages of oncogenic transformation.”
The paper relies on this without support.
Human cells require inactivation of Rb and/or p53 to bypass the major checkpoint that limits replicative lifespan: cellular senescence.
“Human cells require inactivation of Rb and/or p53 to bypass the major checkpoint that limits replicative lifespan: cellular senescence.”
The paper relies on this without support.
Rb/p53 inactivation allows continued cell division beyond senescence, progressive telomere shortening, and entry into crisis, from which only rare survivors emerge.
“Rb/p53 inactivation allows continued cell division beyond senescence, progressive telomere shortening, and entry into crisis, from which only rare survivors will emerge.”
The paper relies on this without support.
Many human tumors that are telomerase positive still have short telomeres.
“The fact that many human tumors that are telomerase positive still have short telomeres supports the idea that telomerase activation occurs late in tumorigenesis.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although enabling cellular growth and survival and masking degenerative phenotypes, these mTerc -/ -p53 mutant mice experience a dramatic increase in cancer incidence, shift in tumor spectrum toward epithelial cancers, and accumulation of marked chromosomal aberrations targeting cancerrelevant loci for amplification and deletion (4-6).”
From Ink4a / Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse (2007) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Specifically, p53 deficiency results in nearcomplete rescue of adverse cellular consequences associated with telomere dysfunction, including cellular growth arrest and apoptosis, progressive organ system atrophy, and physiological compromise.”
From Ink4a / Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse (2007) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Telomere dysfunction appears to engage the p53-dependent double-stranded break DNA damage pathway.”
From Ink4a / Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse (2007) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When the p53 checkpoint is compromised, unchecked genomic instability caused by telomere dysfunction accelerates tumorigenesis as seen in late-generation mTerc -/ -p53 mutant mice (4, 5).”
From Ink4a / Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse (2007) · cites this paper as [4]
Experimental — accuracy not yet measuredIn the citing paper
“By contrast, p53 inactivation alone is sufficient to avoid telomere-induced senescence and apoptosis in mice49,50.”
From Telomeres in cancer: tumour suppression and genome instability (2017) · cites this paper as [49]
In the citing paper
“In the absence of telomerase, continued cell division results in telomere shortening, loss of ‘capping’ function, and p53 activation12-15.”
From Telomere dysfunction induces metabolic and mitochondrial compromise (2011) · cites this paper as [15]
In the citing paper
“p53 deficiency markedly attenuates the degenerative phenotypes associated with telomere dysfunction, whereas constitutively activated p53 accelerates ageing phenotypes15-18.”
From Telomere dysfunction induces metabolic and mitochondrial compromise (2011) · cites this paper as [15]
In the citing paper
“Critically short telomeres induce cellular and tissue defects through checkpoint signaling pathways that converge on the p53 tumor suppressor protein, a well-known cellular stress sensor that enforces cell cycle arrest or cell death in response to diverse stimuli including activated oncogenes, DNA damage and hypoxia (69)”
From Telomeres and telomerase in cancer (2010) · cites this paper as [69]
In the citing paper
“The downstream effector pathways of telomere-induced senescence are largely p53-dependent96, but there may be involvement of the retinoblastoma protein (RB) pathway in some settings97.”
From The telomere syndromes (2012) · cites this paper as [96]
In the citing paper
“Importantly, removal of p53 function rescued many of the cellular defects despite the presence of critically short telomeres, including growth arrest in cell culture, testicular atrophy, intestinal and germ cell apoptosis46.”
From Telomere dysfunction and tumour suppression: the senescence connection (2008) · cites this paper as [46]
In the citing paper
“recent reports of the effect of the mTR deletion in different genetic backgrounds (17, 18) suggest that the role of telomerase in cancer development could be highly context dependent (19).”
From Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death (1999) · cites this paper as [18]
Citations
Cites
The serial cultivation of human diploid cell strains
Hayflick, L., & Moorhead, P. S. (1961) · Experimental Cell Research · doi:10.1016/0014-4827(61)90192-6 · Cited by 8,508
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“INK4a2/2 centration of 10 mM for 3.5 hr. Cells were processed as previouslymice lack functional p19ARF, a modulator of p53 function described (Serrano et al., 1997).activated by inappropiate oncogene activation, but re- tain intact DNA damage–induced p53 activation (Kamijo MEF Transformation…”
MethodInfluentialExtension of Life-Span by Introduction of Telomerase into Normal Human Cells
Bodnar, A. G., Ouellette, M., Frolkis, M., Holt, S. E., Chiu, C.-P., Morin, G. B., Harley, C. B., Shay, J. W., Lichtsteiner, S., & Wright, W. E. (1998) · Science · doi:10.1126/science.279.5349.349 · Cited by 4,975
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,911
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
Land, H., Parada, L. F., & Weinberg, R. A. (1983) · Nature · doi:10.1038/304596a0 · Cited by 2,804
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803
Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
Telomere Shortening and Tumor Formation by Mouse Cells Lacking Telomerase RNA
Blasco, M. A., Lee, H.-W., Hande, M. P., Samper, E., Lansdorp, P. M., DePinho, R. A., & Greider, C. W. (1997) · Cell · doi:10.1016/s0092-8674(01)80006-4 · Cited by 2,108
Self-citation
Cited by
Sorted by citations
Items 301–400 of 975
Using naturally occurring tumours in dogs and cats to study telomerase and cancer stem cell biology
Pang, L. Y., & Argyle, D. J. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.02.010 · Cited by 92
“These tumours exhibit high rates of chromosomal instability [86, 87].”
Recent advances in cancer research: mouse models of tumorigenesis
Herzig, M., & Christofori, G. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00039-2 · Cited by 89
Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma.
Shammas, M. A., Reis, R. J. S., Akiyama, M., Koley, H., Chauhan, D., Hideshima, T., Goyal, R. K., Hurley, L. H., Anderson, K. C., & Munshi, N. C. (2003) · PubMed · Cited by 88
Signaling through estrogen receptors modulates telomerase activity in human prostate cancer
Nanni, S., Narducci, M., Pietra, L. D., Moretti, F., Grasselli, A., Carli, P. D., Sacchi, A., Pontecorvi, A., & Farsetti, A. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15552 · Cited by 92
Telomere repeat binding factors: keeping the ends in check
Karlseder, J. (2003) · Cancer Letters · doi:10.1016/s0304-3835(02)00706-1 · Cited by 88
p53/MDM2 signaling pathway in aging, senescence and tumorigenesis
Huang, Y., Che, X., Wang, P., & Qu, X. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.05.001 · Cited by 99
Cohesin SMC1β protects telomeres in meiocytes
Adelfalk, C., Janschek, J., Revenkova, E., Blei, C., Liebe, B., Göb, E., Alsheimer, M., Benavente, R., de Boer, E., Novak, I., et al. (2009) · The Journal of Cell Biology · doi:10.1083/jcb.200808016 · Cited by 90
“Telomeraseindependent mechanisms for telomere elongation based on homologous recombination between telomeres of different chromosomes (alternative lengthening of telomeres [ALT] pathway) may exist in meiocytes (Chin et al., 1999).”
Espejel, S., Klatt, P., Murcia, J. M., Martín‐Caballero, J., Flores, J. M., Taccioli, G. E., de MURCIA, G., & Blasco, M. A. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200407178 · Cited by 90
“Of note, it has been suggested that genetic instability associated with telomere dysfunction does not drive tumorigenesis in any case unless p53 function is abolished (Chin et al., 1999).”
BackgroundHu, Y., Shi, G. W., Zhang, L., Li, F., Jiang, Y., Jiang, S., Ma, W., Zhao, Y. B., Songyang, Z., & Huang, J. (2016) · Scientific Reports · doi:10.1038/srep32280 · Cited by 87
Short-term gain, long-term pain: the senescence life cycle and cancer
Chan, A. S. L., & Narita, M. (2019) · Genes & Development · doi:10.1101/gad.320937.118 · Cited by 80
“Importantly, these exceptions,where short telomeres counterintuitively promote the incidence of cancer, tend to be associated with a p53 defect (Chin et al. 1999; Artandi et al. 2000).”
BackgroundTelomeres: Implications for Cancer Development
Bernal, A., & Tusell, L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010294 · Cited by 92
“Strikingly, the abrogation of p53 function in mTerc−/− mice with dysfunctional telomeres enabled survival in the face of telomere dysfunction, and rescued many of the associated premature aging phenotypes, but at the expense of facilitating cellular transformation with MYC oncoprotein and GTPase Ras (RAS) [139].”
BackgroundGladdy, R. A., Taylor, M. D., Williams, C. J., Grandal, I., Karásková, J., Squire, J. A., Rutka, J. T., Guidos, C. J., & Danska, J. S. (2003) · Cancer Cell · doi:10.1016/s1535-6108(02)00236-2 · Cited by 85
“First, p53 deficiency prevents apoptosis or cell cycle arrest in response to short telomeres (Chin et al., 1999) or unrepaired RAG-1/2mediated DSB (Guidos et al.”
Do tumor-suppressive mechanisms contribute to organism aging by inducing stem cell senescence?
Pelicci, P. G. (2004) · Journal of Clinical Investigation · doi:10.1172/jci20750 · Cited by 86
Probing p53 biological functions through the use of genetically engineered mouse models
Attardi, L. D., & Donehower, L. A. (2005) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2004.08.022 · Cited by 89
Akiyama, M., Hideshima, T., Shammas, M. A., Hayashi, T., Hamasaki, M., Tai, Y., Richardson, P. G. G., Gryaznov, S. M., Munshi, N. C., & Anderson, K. C. (2003) · PubMed · Cited by 84
RetractedFlores, I., & Blasco, M. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004934 · Cited by 83
The ageing epigenome: Damaged beyond repair?
Sinclair, D. A., & Oberdoerffer, P. (2009) · Ageing Research Reviews · doi:10.1016/j.arr.2009.04.004 · Cited by 86
Immortalization and Transformation of Human Cells
Hahn, W. C. (2002) · Molecules and Cells · doi:10.1016/s1016-8478(23)15045-x · Cited by 84
Takahashi, Y., Kuro‐o, M., & Ishikawa, F. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.210382097 · Cited by 84
Technologically advanced cancer modeling in mice
Tuveson, D. A. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(01)00272-6 · Cited by 80
Maser, R. S., Wong, K., Sahin, E., Xia, H., Naylor, M. L., Hedberg, H. M., Artandi, S. E., & DePinho, R. A. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01354-06 · Cited by 84
“Telomere dysfunction in the germ compartment in the testis results largely in a p53-dependent apoptotic process (17).”
BackgroundInfluentialSelf-citationThe role of p53 in developmental syndromes
Bowen, M. E., & Attardi, L. D. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy087 · Cited by 78
“…from dyskeratosis congenita patients have elevated p53 levels, and loss of Trp53 can rescue the hyperpigmentation phenotype, the skeletal defects, and the testes defects in mouse models of this syndrome (Table 1) (Chin et al., 1999; Else et al., 2009; Vlangos et al., 2009; Pereboeva et al., 2016).”
BackgroundBuilding ‘validated’ mouse models of human cancer
Hann, B. C., & Balmain, A. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00283-0 · Cited by 76
MacKenzie, K. L., Franco, S., May, C., Sadelain, M., & Moore, M. A. S. (2000) · Experimental Cell Research · doi:10.1006/excr.2000.4982 · Cited by 92
Schratz, K. E., Gaysinskaya, V. A., Cosner, Z. L., DeBoy, E. A., Xiang, Z., Kasch-Semenza, L., Florea, L., Shah, P. D., & Armanios, M. Y. (2021) · Journal of Clinical Investigation · doi:10.1172/jci147598 · Cited by 81
Sheng, R., Gu, Z., & Xie, M. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.07.083 · Cited by 77
A role for Brca1 in chromosome end maintenance
McPherson, J. P., Hande, M. P., Poonepalli, A., Lemmers, B., Matysiak‐Zablocki, E., Migon, E., Shehabeldin, A., Porras, A., Karásková, J., Vukovic, B., et al. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl002 · Cited by 79
Cell-Free Fetal DNA, Telomeres, and the Spontaneous Onset of Parturition
Phillippe, M. (2015) · Reproductive Sciences · doi:10.1177/1933719115592714 · Cited by 79
“apoptosis through at least 2 mechanisms: cell death mediated by p53-dependent signaling and by p53-independent events, with the latter possibly related to marked genetic instability due to Ku86 facilitated deleterious DNA fusion events.(110,111) Once apoptosis begins, Multani et al(112) have observed that the telomere…”
BackgroundEmerging roles for telomerase in neuronal development and apoptosis
Mattson, M. P., & Klapper, W. (2001) · Journal of Neuroscience Research · doi:10.1002/1097-4547(20010101)63:1 · Cited by 76
Proliferative lifespan is conserved after nuclear transfer
Clark, A. J., Ferrier, P. M., Aslam, S., Burl, S., Denning, C. N., Wylie, D., Ross, A., Sousa, P. A. D., Wilmut, I., & Cui, W. (2003) · Nature Cell Biology · doi:10.1038/ncb992 · Cited by 77
“In addition, their erosion has been proposed to function as a mitotic clock that controls cell cycle arrest and cellular senescence, because once they shorten below a critical length, they lose the capacity to cap chromosomes effectively, resulting in activation of a DNA damage response mechanis”
Telomere regulation and function during meiosis
Siderakis, M., & Tarsounas, M. (2007) · Chromosome Research · doi:10.1007/s10577-007-1149-7 · Cited by 81
“Interestingly, erratic telomere elongation has been reported in some seminiferous tubules of the p53j/jTercj/j mice (Chin et al. 1999), which may be due to activation of alternative pathways of telomere lengthening.”
InfluentialTelomerase-independent Regulation of ATR by Human Telomerase RNA
Kedde, M., le Sage, C., Duursma, A. M., Zlotorynski, E., van Leeuwen, B., Nijkamp, W., Beijersbergen, R. L., & Agami, R. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m607676200 · Cited by 78
Bejarano, L., Schuhmacher, A. J., Méndez, M., Megı́as, D., Blanco‐Aparicio, C., Martı́nez, S., Pastor, J., Squatrito, M., & Blasco, M. A. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.006 · Cited by 79
“However, both telomerase abrogation in mouse cancer models and human clinical trials with telomerase inhibitors have shown limited benefit, as telomerase inhibition only affects cell viability when telomeres are short, and tumors are heterogeneous in terms of telomere length (Middleton et al., 2014; Parkhurst et al.,…”
BackgroundInfluentialCayuela, M. L., Flores, J. M., & Blasco, M. A. (2005) · EMBO Reports · doi:10.1038/sj.embor.7400359 · Cited by 77
Telomere-related Markers for Cancer
Yuan, X., Dai, M., & Xu, D. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200106145340 · Cited by 77
Association between lncrna PCGEM1 polymorphisms and prostate cancer risk
Xue, Y., Wang, M., Kang, M., Wang, Q., Wu, B., Chu, H., Zhong, D., Qin, C., Yin, C., Zhang, Z., et al. (2013) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2013.6 · Cited by 75
Signaling through estrogen receptors modulates telomerase activity in human prostate cancer
Nanni, S., Narducci, M., Pietra, L. D., Moretti, F., Grasselli, A., Carli, P. D., Sacchi, A., Pontecorvi, A., & Farsetti, A. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215552 · Cited by 75
Therapeutic targeting of replicative immortality
Yaswen, P., MacKenzie, K. L., Keith, W. N., Hentosh, P., Rodier, F., Zhu, J., Firestone, G. L., Matheu, A., Carnero, A., Bilsland, A. E., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.007 · Cited by 82
“Deletion of p53 attenuated the ellular and organismal effects of telomere dysfunction [45,96].”
DNA double-strand breaks: A potential causative factor for mammalian aging?
Li, H., Mitchell, J. R., & Hasty, P. (2008) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2008.02.002 · Cited by 76
“, 2000) and for the adverse cellular and organismal problems and low cancer incidence associated with telomere erosion (Chin et al., 1999).”
BackgroundMasutomi, K., & Hahn, W. C. (2003) · Cancer Letters · doi:10.1016/s0304-3835(02)00703-6 · Cited by 75
“Studies in both human and murine cells indicate that shortened telomeres in these post-senescent cells no longer retain the capacity to protect chromosomes from degradation and damage, suggesting a plausible mechanism for the chromosomal instability and aneuploidy observed when cells enter crisis [44–47].”
BackgroundDyskeratosis congenita, telomeres and human ageing
Marciniak, R. A., Johnson, F. B., & Guarente, L. (2000) · Trends in Genetics · doi:10.1016/s0168-9525(00)01984-3 · Cited by 74
The mTOR pathway is necessary for survival of mice with short telomeres
Ferrara‐Romeo, I., Martínez, P., Saraswati, S., Whittemore, K., Graña‐Castro, O., Poluha, L. T., Serrano, R., Hernández-Encinas, E., Blanco‐Aparicio, C., Flores, J. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14962-1 · Cited by 76
Telomerase activation causes vascular smooth muscle cell proliferation in genetic hypertension 1
Cao, Y., Li, H., Mu, F., Ebisui, O., Funder, J. W., & Liu, J. (2002) · The FASEB Journal · doi:10.1096/cj.01-0447fje · Cited by 72
Melanoma Cells Express Elevated Levels of Phosphorylated Histone H2AX Foci
Warters, R. L., Adamson, P. J., Pond, C. D., & Leachman, S. A. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23674.x · Cited by 77
p53: at the crossroad between cancer and ageing
Papazoglu, C., & Mills, A. (2007) · The Journal of Pathology · doi:10.1002/path.2086 · Cited by 75
“Some of the phenotypes of accelerated ageing could be rescued by generating telomerase-deficient mice in a p53-deficient background [69].”
Martínez, P., & Blasco, M. A. (2018) · Circulation Research · doi:10.1161/circresaha.118.312202 · Cited by 74
“and genomic instability triggering age-associated diseases like cancer.(53) Of particular relevance is the fact that short telomeres trigger replicative senescence.”
BackgroundAttardi, L. D. (2004) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2004.04.019 · Cited by 73
Multiple Mechanisms of Telomere Maintenance Exist in Liposarcomas
Johnson, J. E., Varkonyi, R. J., Schwalm, J., Cragle, R., Klein–Szanto, A. J., Patchefsky, A. S., Cukierman, E., von Mehren, M., & Broccoli, D. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0684 · Cited by 72
Markers of cellular senescence.
Carnero, A. (2013) · Methods in Molecular Biology · doi:10.1007/978-1-62703-239-1_4 · Cited by 68
Phosphorylation of H2AX at Short Telomeres in T Cells and Fibroblasts
Hao, L.-Y., Strong, M. A., & Greider, C. W. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403924200 · Cited by 71
Self-citationTelomeres, telomerase, and cancer: life on the edge of genomic stability
Oulton, R., & Harrington, L. A. (2000) · Current Opinion in Oncology · doi:10.1097/00001622-200001000-00013 · Cited by 71
Mechanisms of chromosome-end protection
Cervantes, R. B., & Lundblad, V. (2002) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(02)00325-3 · Cited by 71
The Regulation of Cellular Functions by the p53 Protein: Cellular SenescencePreprint
Tonnessen-Murray, C. A., Lozano, G., & Jackson, J. G. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026112 · Cited by 76
“Mice engineered to lack telomerase activity are tumor prone, and this is accelerated by p53 loss (Chin et al. 1999; Rudolph et al. 1999).”
BackgroundThe Medical Genome Reference Bank contains whole genome and phenotype data of 2570 healthy elderly
Pinese, M., Lacaze, P., Rath, E. M., Stone, A., Brion, M.-J., Ameur, A., Nagpal, S., Puttick, C., Husson, S., Degrave, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14079-0 · Cited by 70
Change in Peripheral Blood Leukocyte Telomere Length and Mortality in Breast Cancer Survivors
Duggan, C. R., Risques, R. A., Alfano, C. M., Prunkard, D. E., Imayama, I., Holte, S., Baumgartner, K. B., Baumgartner, R., Bernstein, L., Ballard-Barbash, R. R., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju035 · Cited by 70
Shammas, M. A., Koley, H., Beer, D. G., Li, C., Goyal, R. K., & Munshi, N. C. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.01.026 · Cited by 70
Telomeres and the DNA damage response: why the fox is guarding the henhouse
Maser, R. S., & DePinho, R. A. (2004) · DNA repair · doi:10.1016/j.dnarep.2004.05.009 · Cited by 69
Self-citationPech, M. F., Garbuzov, A., Hasegawa, K., Sukhwani, M., Zhang, R. J., Benayoun, B. A., Brockman, S. A., Lin, S., Brunet, A., Orwig, K. E., et al. (2015) · Genes & Development · doi:10.1101/gad.271783.115 · Cited by 74
“As previously observed, late-generation testes exhibited atrophy and loss of germ cell cellularity in a variable and stochastic fashion (Supplemental Fig. 6B,C; Chin et al. 1999).”
Self-citationSequence‐specific binding property of Arabidopsis thaliana telomeric DNA binding protein 1 (AtTBP1)
Hwang, M. G., Chung, I. K., Kang, B. G., & Cho, M. H. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02685-0 · Cited by 68
Qi, L., Strong, M. A., Karim, B. O., Armanios, M. Y., Huso, D. L., & Greider, C. W. (2003) · PubMed · Cited by 68
Self-citationRole of telomere dysfunction in aging and its detection by biomarkers
von Figura, G., Hartmann, D., Song, Z., & Rudolph, K. L. (2009) · Journal of Molecular Medicine · doi:10.1007/s00109-009-0509-5 · Cited by 70
Replicative senescence and the art of counting
von Zglinicki, T. (2003) · Experimental Gerontology · doi:10.1016/j.exger.2003.09.015 · Cited by 69
Barradas, M., Gonos, E. S., Zebedee, Z., Kolettas, E., Petropoulou, C., Delgado, M. D., León, J., Hara, E., & Serrano, M. (2002) · Experimental Cell Research · doi:10.1006/excr.2001.5434 · Cited by 67
REVIEW PAPER: Origin and Molecular Pathology of Adrenocortical Neoplasms
Bielińska, M., Parviainen, H., Kiiveri, S., Heikinheimo, M., & Wilson, D. B. (2009) · Veterinary Pathology · doi:10.1354/vp.08-vp-0179-w-rev · Cited by 68
Telomere maintenance mechanisms as a target for drug development
Bearss, D. J., Hurley, L. H., & Hoff, D. D. V. (2000) · Oncogene · doi:10.1038/sj.onc.1204092 · Cited by 67
Control of Cellular Aging, Tissue Function, and Cancer by p53 Downstream of TelomeresPreprint
Roake, C. M., & Artandi, S. E. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026088 · Cited by 70
“Late-generation TERC mice showed very high levels of apoptosis in multiple organs, including testis, lymphoid tissue, and intestinal epithelium, coincident with stabilization and activation of p53 (Chin et al. 1999).”
Self-citationImplications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis
Güneş, Ç., Wezel, F., Southgate, J., & Bolenz, C. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0001-5 · Cited by 68
Short telomeres in aggressive non-Hodgkin's lymphoma as a risk factor in lymphomagenesis
Widmann, T., Herrmann, M., Taha, N., König, J., & Pfreundschuh, M. G. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2007.03.009 · Cited by 64
McKnight, T. D., & Shippen, D. E. (2004) · The Plant Cell · doi:10.1105/tpc.160470 · Cited by 68
“Double mutants in mice lacking both telomerase and p53 survive longer than single telomerase-null mutants, but the absence of p53 merely postpones inevitable cell death (Chin et al., 1999).”
BackgroundClonal hematopoiesis in the inherited bone marrow failure syndromes
Tsai, F. D., & Lindsley, R. C. (2020) · Blood · doi:10.1182/blood.2019000990 · Cited by 69
Lechel, A., Holstege, H. H., Begus, Y., Schienke, A., Kamino, K., Lehmann, U., Kubicka, S., Schirmacher, P., Jonkers, J., & Rudolph, K. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.01.045 · Cited by 66
Sirtuin 1, stem cells, aging, and stem cell aging
Mantel, C., & Broxmeyer, H. E. (2008) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3283043819 · Cited by 65
The role of telomeres and telomerase in the pathology of human cancer and aging
Shin, J., Hong, A., Solomon, M. J., & Lee, C. S. (2006) · Pathology · doi:10.1080/00313020600580468 · Cited by 66
p16 and ARF: activation of teenage proteins in old age
Ande, S., & Rudolph, K. L. (2004) · Journal of Clinical Investigation · doi:10.1172/jci23437 · Cited by 64
Kim, H., You, S., Farris, J., Kong, B. C., Christman, S. A., Foster, L. K., & Foster, D. N. (2002) · Experimental Cell Research · doi:10.1006/excr.2001.5420 · Cited by 65
Schratz, K. E., Flasch, D. A., Atik, C. C., Cosner, Z. L., Blackford, A. L., Yang, W., Gable, D. L., Vellanki, P. J., Xiang, Z., Gaysinskaya, V. A., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.03.005 · Cited by 64
Sperka, T., Song, Z., Morita, Y., Nalapareddy, K., Guachalla, L. M., Lechel, A., Begus‐Nahrmann, Y., Burkhalter, M. D., Mach, M., Schlaudraff, F., et al. (2011) · Nature Cell Biology · doi:10.1038/ncb2388 · Cited by 63
“Deletion of Trp53 rescued apoptosis and spermatogenesis in the testis of mice harbouring dysfunctional telomere”
Polymorphisms in Telomere Maintenance Genes and Risk of Lung Cancer
Choi, J. E., Kang, H., Jang, J. S., Choi, Y. Y., Kim, M. J., Kim, J. S., Jeon, H., Lee, W. K., Ick, S., Kim, C. H., et al. (2009) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-0323 · Cited by 63
“For example, p53 plays an important role in stem cell checkpoints induced by telomere shortening (33), and checkpoint failure cooperates with telomere dysfunction to induce chromosomal”
Mattson, M. P. (2001) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(01)00221-4 · Cited by 62
“Conversely, TERT expression is suppressed by pro-apoptotic transcription factors such as p53 (Chin et al., 1999) and Mad (Xu et al., 2000).”
Else, T., Trovato, A., Kim, A. C., Wu, Y., Ferguson, D. O., Kuick, R. D., Lucas, P. C., & Hammer, G. D. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.04.011 · Cited by 62
“Telomere dysfunction of Terc / mice leads to the accumulation of genomic alterations and the development of tumors (Chin et al., 1999).”
InfluentialThe crossroads between cancer stem cells and aging
Franco, S. S., Raveh-Amit, H., Kobolák, J., Al-Qahtani, M. H., Mobasheri, A., & Dinnyés, A. (2015) · BMC Cancer · doi:10.1186/1471-2407-15-s1-s1 · Cited by 63
Chromosomal Instability in Oral Cancer Cells
Reshmi, S. C., & Gollin, S. M. (2005) · Journal of Dental Research · doi:10.1177/154405910508400203 · Cited by 62
“When telomeres become too short, programmed cell death is initiated through activation of TP53-mediated apoptosis (Chin et al., 1999).”
Role of telomere in endothelial dysfunction in atherosclerosis
Minamino, T., & Komuro, I. (2002) · Current Opinion in Lipidology · doi:10.1097/00041433-200210000-00010 · Cited by 62
The price of tumour suppression?
Ferbeyre, G., & Lowe, S. W. (2002) · Nature · doi:10.1038/415026a · Cited by 62
Modeling chromosomal instability and epithelial carcinogenesis in the telomerase-deficient mouse
Chang, S. S., Khoo, C., & DePinho, R. A. (2001) · Seminars in Cancer Biology · doi:10.1006/scbi.2000.0374 · Cited by 64
Self-citationp53 downregulates the Fanconi anaemia DNA repair pathway
Jaber, S., Toufektchan, E., Lejour, V., Bardot, B., & Toledo, F. (2016) · Nature Communications · doi:10.1038/ncomms11091 · Cited by 61
Telomere dysfunction and genome instability
Frías-López, C. (2012) · Frontiers in bioscience · doi:10.2741/4044 · Cited by 66
Telomere dysfunction and cell survival: roles for distinct TIN2-containing complexes
Kim, S., Davalos, A. R., Heo, S., Rodier, F., Zou, Y. S., Beausejour, C. M., Kaminker, P. G., Yannone, S. M., & Campisi, J. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200710028 · Cited by 62
Telomere structure, function and maintenance in Arabidopsis
Říha, K., & Shippen, D. E. (2003) · Chromosome Research · doi:10.1023/a:1022892010878 · Cited by 61
“The p53 tumor suppressor is a key component in the response to uncapped telomeres (Chin et al. 1999, Smogorzewska & de Lange 2002).”
The Role of Glial Cell Senescence in Alzheimer's Disease
Alshaebi, F., Sciortino, A., & Kayed, R. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70051 · Cited by 60
“Accordingly, increased expression of p16 INK4A , p21, WAF1/CIP1 and p53 with age has been reported in several tissues, and their removal has been shown to rescue aging-related phenotypes in mice (Chin et al. 1999; Baker et al. 2008; Janzen et al. 2006; Sato et al. 2015).”
Wang, J., Morita, Y., Han, B., Niemann, S., Löffler, B., & Rudolph, K. L. (2016) · Nature Cell Biology · doi:10.1038/ncb3342 · Cited by 64
Roles of Apoptosis and Cellular Senescence in Cancer and Aging
Cerella, C., Grandjenette, C., Dicato, M. A., & Diederich, M. F. (2016) · Current Drug Targets · doi:10.2174/1389450116666150202155915 · Cited by 64
Multiple cancer pathways regulate telomere protection
Bejarano, L., Bosso, G., Louzame, J., Serrano, R., Gómez‐Casero, E., Martinez-Torrecuadrada, J. L., Martı́nez, S., Blanco‐Aparicio, C., Pastor, J., & Blasco, M. A. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201910292 · Cited by 56
“…most likely due to the fact that a telomerase abrogation would only affect critically short telomeres, and tumors are heterogeneous in terms of telomere length (Chin et al, 1999; Greenberg et al, 1999; Gonzalez-Suarez et al, 2000; Parkhurst et al, 2004; Perera et al, 2008; Middleton et al, 2014).”
Stem cells, telomerase and dyskeratosis congenita
Mason, P. J. (2003) · BioEssays · doi:10.1002/bies.10229 · Cited by 58
“The exception to this is in a p53-deficient background when p53 deficiency and telomere dysfunction co-operate to accelerate carcinogenesis.((50))”
Telomeres and cancer: a tale with many endings
Blasco, M. A. (2003) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(02)00011-4 · Cited by 56
The fabric of cancer cell biology—Weaving together the strands
Klausner, R. D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00020-x · Cited by 57
Kelly, D. P. (2011) · Nature · doi:10.1038/nature09896 · Cited by 62
POT1-TPP1 telomere length regulation and disease
Aramburu, T. M., Plucinsky, S. M., & Skordalakes, E. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.06.040 · Cited by 58
“senescence and continue proliferating, further shortening telomeres to a critical length [88,89].”
Rearrangements of ribosomal DNA clusters in late generation telomerase-deficient Arabidopsis
Široký, J., Žlůvová, J., Říha, K., Shippen, D. E., & Vyskot, B. (2003) · Chromosoma · doi:10.1007/s00412-003-0251-7 · Cited by 57
Ding, L., Li, L. L., Yang, H. J., Tao, Y. G., Ye, M., Shi, Y., Tang, M., Wei, Y., Li, X. L., Gong, J. P., et al. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.04.012 · Cited by 57
Metadata
- Authors
- Chin, L., Artandi, S. E., Shen, Q., Tam, A., Lee, S.-L., Gottlieb, G. J., Greider, C. W., & DePinho, R. A.
- Affiliations
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- Quest Diagnostics (United States) (US)
- Johns Hopkins University (US)
- Corresponding author
- DePinho, Ronald A
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 1999-05
- Volume
- 97
- Issue
- 4
- Pages
- 527-538
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W2027779909
- Cited by
- 979
- References
- 44
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 18 · 2023: 21 · 2022: 15 · 2021: 22 · 2020: 15 · 2019: 26 · 2018: 24 · 2017: 23 · 2016: 32 · 2015: 34 · 2014: 23 · 2013: 40 · 2012: 51
- FWCI
- 36.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01hd028317-05, 5r01hd034880-04, 5k08ar002104-04)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (K08AR02104-01)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD34880, R01 HD28317)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Keywords
- p53, telomere dysfunction, telomere shortening, telomerase deficiency, telomere crisis, carcinogenesis, genomic instability, tumor suppression, apoptosis, growth arrest, telomere length
- MeSH terms
- Animals, Male, Mice, Inbred C57BL, Neoplasms, Phenotype, Spermatozoa, Testis, Tumor Suppressor Protein p53, Telomere, Apoptosis, Telomerase, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
